Cross-Sector entity
Wall Street Zen is the most frequent co-covered peer, appearing in 7 of the 12 tracked stories. That works out to roughly 2.2 stories per week across a 38-day span. The busiest single day carried 4. pharma accounts for 6 of the 12 tracked stories, while 5 other categories carry the remainder.
12 verified stories tracked
Last mentioned: Aug 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Wall Street Zen is the most frequent co-covered peer, appearing in 7 of the 12 tracked stories. That works out to roughly 2.2 stories per week across a 38-day span. The busiest single day carried 4. pharma accounts for 6 of the 12 tracked stories, while 5 other categories carry the remainder. This profile follows 12 Cross-Sector stories mentioning HC Wainwright across the period from July 6, 2026 to August 12, 2026. Negative sentiment appears in 0% of the tracked stories. Each carries 2.1 original sources on average.
Computed from the 12 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering HC Wainwright. Shared-story counts are live from our verified record — not editorial picks.
Schikan sells 30,712 shares
Schikan sold an additional 30,712 shares at $35.49, totaling $1,089,969.
HC Wainwright reiterates buy rating
HC Wainwright reaffirmed its buy rating on Pharvaris shares.
UBS sets $74 price target
UBS Group issued a research note with a $74 price objective on Pharvaris.
Q1 earnings beat
Pharvaris reported Q1 EPS of -$0.70, beating the consensus estimate of -$0.82.
Weiss Ratings issues sell (d-) rating
Weiss Ratings reaffirmed a sell rating on Pharvaris shares, citing financial risks.
Wedbush raises price target to $42
Wedbush lifted its price target on Pharvaris from $41 to $42 with an outperform rating.
Shares of Entera Bio slipped 0.6% to $1.54 on 78% below-average volume, but analysts remain deeply split: HC Wainwright reiterates buy while Weiss Ratings maintains a sell. The $9.00 consensus target implies roughly 484% upside for the $75.91M microcap biotech.
Source: dailypolitical.com · tickerreport.com
Palvella Therapeutics stock sank 12.4% Monday with no news, highlighting biotech liquidity risk. Analyst consensus target of $199.53 implies 45% upside, but earnings miss and two sell ratings complicate the picture for biotech investors.
Source: dailypolitical.com · tickerreport.com
Halozyme Therapeutics posted a massive Q2 beat and raised FY2026 EPS guidance to $8.65-$9.00, well above the $8.02 consensus, triggering a two-day stock surge past $103. With a forward P/E near 11.5x and a PEG ratio of 0.36, the market is repricing the stock after realizing the royalty growth was underestimated.
Halozyme's Q2 2026 earnings showcased accelerating adoption of its ENHANZE drug delivery technology, with royalties from subcutaneous biologics like DARZALEX FASPRO pushing revenue up 47.7% YoY. The company issued FY2026 EPS guidance of $8.65-$9.00, handily beating consensus, signaling sustained growth from its partnered pipeline.
Source: dailypolitical.com · themarketsdaily.com
Wall Street Zen’s hold upgrade caps a series of mixed analyst actions on Talphera, whose stock trades at $1.41 despite a $3.00 average target. Institutional positioning and a technical breakout suggest the market may be repricing a depressed small-cap. For investors, the gap represents both a unique opportunity and a cautionary tale of biotech volatility.
Analyst action pushes Talphera into the spotlight as a deeply undervalued biotech, with a $3.00 average target offering over 100% upside. Recent earnings beat and institutional buying add to the narrative. Two buy initiations from specialized firms highlight confidence in the pain management pipeline.
Source: themarketsdaily.com · dailypolitical.com
Spyglass Pharma's stock plunges to a new 52-week low of $17.56 despite a consensus 'Moderate Buy' rating and an average analyst target of $45. For biotech investors, the 156% upside potential must be weighed against a recent earnings miss and a downgrade to sell, raising questions about near-term pipeline catalysts.
Source: tickerreport.com · dailypolitical.com
Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Source: tickerreport.com · dailypolitical.com
HC Wainwright and Needham lowered price targets on Circle Internet Group but maintained Buy ratings as analysts remain split on the stablecoin issuer. The stock trades at $63.48, far below the consensus target of $100.06, highlighting both opportunity and risk.
Two investment banks cut their price targets on Circle Internet Group, the firm behind the USDC stablecoin, citing near-term headwinds—but both maintained Buy ratings with triple-digit upside potential. The stock’s deep pullback from its $189 high reflects broader crypto market caution.
Source: Bbns · The Lincolnian Online
Director Johannes Schikan sold $1.33 million in Pharvaris stock just as the company approaches critical Phase 3 readouts for its oral HAE therapy. With analysts split and institutions buying, the insider move adds a wrinkle to the risk-reward calculus ahead of binary clinical data.
Source: The Lincolnian Online · Bbns
REGENXBIO Chief Medical Officer Steve Pakola offloaded 56,333 shares for $688,756 following a disastrous Q1 miss, but analysts maintain price targets implying up to 99% upside. The insider sales add tension to a gene therapy story already defined by high risk and potential reward.
Source: Zolmax · Markets Daily
